Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,966 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme.
Dubé MP, Chazara O, Lemaçon A, Asselin G, Provost S, Barhdadi A, Lemieux Perreault LP, Mongrain I, Wang Q, Carss K, Paul DS, Cunningham JW, Rouleau J, Solomon SD, McMurray JJV, Yusuf S, Granger CB, Haefliger C, de Denus S, Tardif JC. Dubé MP, et al. Among authors: yusuf s. ESC Heart Fail. 2022 Oct;9(5):2997-3008. doi: 10.1002/ehf2.14026. Epub 2022 Jun 23. ESC Heart Fail. 2022. PMID: 35736394 Free PMC article.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. McMurray JJ, et al. Among authors: yusuf s. Lancet. 2003 Sep 6;362(9386):767-71. doi: 10.1016/S0140-6736(03)14283-3. Lancet. 2003. PMID: 13678869 Clinical Trial.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Granger CB, et al. Among authors: yusuf s. Lancet. 2003 Sep 6;362(9386):772-6. doi: 10.1016/S0140-6736(03)14284-5. Lancet. 2003. PMID: 13678870 Clinical Trial.
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Solomon SD, et al. Among authors: yusuf s. Circulation. 2004 Oct 12;110(15):2180-3. doi: 10.1161/01.CIR.0000144474.65922.AA. Epub 2004 Oct 4. Circulation. 2004. PMID: 15466644 Clinical Trial.
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Young JB, et al. Among authors: yusuf s. Circulation. 2004 Oct 26;110(17):2618-26. doi: 10.1161/01.CIR.0000146819.43235.A9. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492298 Clinical Trial.
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
O'Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, Granger C, Olofsson B, Young JB, Swedberg K. O'Meara E, et al. Among authors: yusuf s. Eur Heart J. 2004 Nov;25(21):1920-6. doi: 10.1016/j.ehj.2004.07.025. Eur Heart J. 2004. PMID: 15522471 Clinical Trial.
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA. O'Meara E, et al. Among authors: yusuf s. Eur J Heart Fail. 2005 Jun;7(4):650-6. doi: 10.1016/j.ejheart.2005.01.021. Eur J Heart Fail. 2005. PMID: 15921807 Free article.
Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, Hall C, Latini R, Afzal R, Floras J, Masson S, McKelvie RS; Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators. Yan RT, et al. Among authors: yusuf s. Am J Cardiol. 2005 Sep 1;96(5):698-704. doi: 10.1016/j.amjcard.2005.04.048. Am J Cardiol. 2005. PMID: 16125499 Clinical Trial.
1,966 results